Absci (ABSI) EPS (Weighted Average and Diluted) (2020 - 2026)
Absci's (ABSI) quarterly EPS (Weighted Average and Diluted) came in at -$0.19 in Q1 2026, up 9.52% year-on-year from -$0.17 in Q1 2025, and little changed quarter-over-quarter from -$0.19 in Q4 2025.
Absci (ABSI) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Absci has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.19 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.19, up 9.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.82 (up 11.83% YoY), and the FY2025 annual result was -$0.84, up 10.64% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.19 for Q1 2026 at Absci, roughly flat from -$0.19 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.19 in Q4 2025 to a low of -$0.45 in Q2 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.24 (2023), against an average of -$0.25.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 86.61% in 2022, while the deepest fall reached 362.5% in 2022.
- Absci's EPS (Weighted Average and Diluted) stood at -$0.21 in 2022, then fell by 19.05% to -$0.25 in 2023, then fell by 4.0% to -$0.26 in 2024, then rose by 26.92% to -$0.19 in 2025, then retreated by 0.0% to -$0.19 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.19 (Q1 2026), -$0.19 (Q4 2025), and -$0.2 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | -0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -0.19 |
| Sep 30, 2025 | -0.20 |
| Jun 30, 2025 | -0.24 |
| Mar 31, 2025 | -0.21 |
| Dec 31, 2024 | -0.26 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.22 |
| Mar 31, 2024 | -0.22 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.45 |
| Mar 31, 2023 | -0.26 |
| Dec 31, 2022 | -0.21 |
| Sep 30, 2022 | -0.30 |
| Jun 30, 2022 | -0.32 |
| Mar 31, 2022 | -0.33 |
| Dec 31, 2021 | 0.08 |
| Sep 30, 2021 | -0.33 |
| Jun 30, 2021 | -2.39 |